Use of aromatase inhibitors, which are known to reduce endogenous oestrogen levels, as adjuvant therapy had a lower risk of endometrial cancer, compared with that of patients who were treated with tamoxifen, results of a new study show. In this study, Rowan Chleblowski and colleagues (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA, USA) examined the rec...